| Item Type | Name |
|
Concept
|
Antineoplastic Agents
|
|
Concept
|
Antineoplastic Agents, Alkylating
|
|
Concept
|
Antineoplastic Agents, Hormonal
|
|
Concept
|
Antineoplastic Agents, Phytogenic
|
|
Academic Article
|
Study of cohort-specific consent and patient control in phase I cancer trials.
|
|
Academic Article
|
New chemotherapy regimens for advanced bladder cancer.
|
|
Academic Article
|
Phase I Trial of ISIS 5132, an antisense oligonucleotide inhibitor of c-raf-1, administered by 24-hour weekly infusion to patients with advanced cancer.
|
|
Academic Article
|
Development of target-based antineoplastic agents.
|
|
Academic Article
|
Flavopiridol metabolism in cancer patients is associated with the occurrence of diarrhea.
|
|
Academic Article
|
Flavopiridol, a novel cyclin-dependent kinase inhibitor, in metastatic renal cancer: a University of Chicago Phase II Consortium study.
|
|
Academic Article
|
Kidney cancer.
|
|
Academic Article
|
Multicenter phase II trial of interleukin-2, interferon-alpha, and 13-cis-retinoic acid in patients with metastatic renal-cell carcinoma.
|
|
Academic Article
|
In vitro evaluation of flavopiridol, a novel cell cycle inhibitor, in bladder cancer.
|
|
Academic Article
|
Gemcitabine doublets in advanced urothelial cancer.
|
|
Academic Article
|
A phase II trial of intravenous gemcitabine and 5-fluorouracil with subcutaneous interleukin-2 and interferon-alpha in patients with metastatic renal cell carcinoma.
|
|
Academic Article
|
New trial designs to assess antitumor and antiproliferative agents in prostate cancer.
|
|
Academic Article
|
Randomized study of three different doses of suramin administered with a fixed dosing schedule in patients with advanced prostate cancer: results of intergroup 0159, cancer and leukemia group B 9480.
|
|
Academic Article
|
A phase II trial of weekly intravenous ranpirnase (Onconase), a novel ribonuclease in patients with metastatic kidney cancer.
|
|
Academic Article
|
Phase II trial of ZD1839 in recurrent or metastatic squamous cell carcinoma of the head and neck.
|
|
Academic Article
|
A phase II trial of oral temozolomide in patients with metastatic renal cell cancer.
|
|
Academic Article
|
Acute bilateral abducens paralysis due to oxaliplatin.
|
|
Academic Article
|
Angiogenesis inhibitors in genitourinary cancers.
|
|
Academic Article
|
Clinical trial designs for cytostatic agents.
|
|
Academic Article
|
9-Nitrocamptothecin as second line chemotherapy for men with progressive, metastatic, hormone refractory prostate cancer: Results of the CALGB 99901.
|
|
Academic Article
|
Depletion of normal B cells with rituximab as an adjunct to IL-2 therapy for renal cell carcinoma and melanoma.
|
|
Academic Article
|
Randomized discontinuation design: application to cytostatic antineoplastic agents.
|
|
Academic Article
|
Novel kinase inhibitors in renal cell carcinoma: progressive development of static agents.
|
|
Academic Article
|
Successful implementation of the randomized discontinuation trial design: an application to the study of the putative antiangiogenic agent carboxyaminoimidazole in renal cell carcinoma--CALGB 69901.
|
|
Academic Article
|
A phase II study of nilutamide in men with prostate cancer after the failure of flutamide or bicalutamide therapy.
|
|
Academic Article
|
A Phase II study of oxaliplatin in urothelial cancer.
|
|
Academic Article
|
The role of systemic chemotherapy in the treatment of kidney cancer.
|
|
Academic Article
|
Targeted agents for the treatment of advanced renal cell carcinoma.
|
|
Academic Article
|
Phase II placebo-controlled randomized discontinuation trial of sorafenib in patients with metastatic renal cell carcinoma.
|
|
Academic Article
|
Inflammation of actinic keratoses subsequent to therapy with sorafenib, a multitargeted tyrosine-kinase inhibitor.
|
|
Academic Article
|
Development of growth inhibitory agents in urological and other malignancies.
|
|
Academic Article
|
The randomized discontinuation trial: a phase II design to assess growth-inhibitory agents.
|
|
Academic Article
|
A Phase I/II study of GTI-2040 and capecitabine in patients with renal cell carcinoma.
|
|
Academic Article
|
Sorafenib in advanced clear-cell renal-cell carcinoma.
|
|
Academic Article
|
Chemotherapy for bladder cancer: treatment guidelines for neoadjuvant chemotherapy, bladder preservation, adjuvant chemotherapy, and metastatic cancer.
|
|
Academic Article
|
Chromosomes, hypoxia, angiogenesis, and trial design: a brief history of renal cancer drug development.
|
|
Academic Article
|
Phase 2 trial of talactoferrin in previously treated patients with metastatic renal cell carcinoma.
|
|
Academic Article
|
A Phase II trial of suramin monthly x 3 for hormone-refractory prostate carcinoma.
|
|
Academic Article
|
Randomized, double-blind, placebo-controlled phase II trial of maintenance sunitinib versus placebo after chemotherapy for patients with advanced urothelial carcinoma: scientific rationale and study design.
|
|
Academic Article
|
Dynamic contrast-enhanced magnetic resonance imaging pharmacodynamic biomarker study of sorafenib in metastatic renal carcinoma.
|
|
Academic Article
|
Vorinostat in advanced prostate cancer patients progressing on prior chemotherapy (National Cancer Institute Trial 6862): trial results and interleukin-6 analysis: a study by the Department of Defense Prostate Cancer Clinical Trial Consortium and University of Chicago Phase 2 Consortium.
|
|
Academic Article
|
A phase II trial of the Src-kinase inhibitor AZD0530 in patients with advanced castration-resistant prostate cancer: a California Cancer Consortium study.
|
|
Academic Article
|
Vinflunine in platinum-pretreated patients with locally advanced or metastatic urothelial carcinoma: results of a large phase 2 study.
|
|
Academic Article
|
Phase II study of the efficacy and safety of oral GD0039 in patients with locally advanced or metastatic renal cell carcinoma.
|
|
Academic Article
|
Sorafenib for treatment of renal cell carcinoma: Final efficacy and safety results of the phase III treatment approaches in renal cancer global evaluation trial.
|
|
Academic Article
|
New therapeutic options for renal cell carcinoma.
|
|
Academic Article
|
Sorafenib.
|
|
Academic Article
|
New targets, therapies, and toxicities: lessons to be learned.
|
|
Academic Article
|
Ambulatory monitoring detects sorafenib-induced blood pressure elevations on the first day of treatment.
|
|
Academic Article
|
Safety and efficacy results of the advanced renal cell carcinoma sorafenib expanded access program in North America.
|
|
Academic Article
|
A phase II study of ixabepilone (BMS-247550) in metastatic renal-cell carcinoma.
|
|
Academic Article
|
A pilot study of the vulnerable elders survey-13 compared with the comprehensive geriatric assessment for identifying disability in older patients with prostate cancer who receive androgen ablation.
|
|
Academic Article
|
Safety and efficacy of sorafenib in elderly patients treated in the North American advanced renal cell carcinoma sorafenib expanded access program.
|
|
Academic Article
|
Phase I dose escalation and pharmacokinetic study of AZD2171, an inhibitor of the vascular endothelial growth factor receptor tyrosine kinase, in patients with hormone refractory prostate cancer (HRPC).
|
|
Academic Article
|
A phase I study of continuous infusion cilengitide in patients with solid tumors.
|
|
Academic Article
|
Cediranib in patients with malignant mesothelioma: a phase II trial of the University of Chicago Phase II Consortium.
|
|
Academic Article
|
Pharmacogenomics in early-phase oncology clinical trials: is there a sweet spot in phase II?
|
|
Academic Article
|
Phase II randomized, double-blind, placebo-controlled study of tasquinimod in men with minimally symptomatic metastatic castrate-resistant prostate cancer.
|
|
Academic Article
|
Developing drugs that do not cause tumor regression.
|
|
Academic Article
|
Phase II, two-stage, single-arm trial of the histone deacetylase inhibitor (HDACi) romidepsin in metastatic castration-resistant prostate cancer (CRPC).
|
|
Academic Article
|
Cognitive effects of androgen deprivation therapy in an older cohort of men with prostate cancer.
|
|
Academic Article
|
Randomized, double-blind, placebo-controlled phase III trial comparing docetaxel and prednisone with or without bevacizumab in men with metastatic castration-resistant prostate cancer: CALGB 90401.
|
|
Academic Article
|
Phase II study of Aflibercept (VEGF-Trap) in patients with recurrent or metastatic urothelial cancer, a California Cancer Consortium Trial.
|
|
Academic Article
|
A phase II study of the efficacy and safety of AMG 102 in patients with metastatic renal cell carcinoma.
|
|
Academic Article
|
A phase II study of PS-341 (Bortezomib) in advanced or metastatic urothelial cancer. A trial of the Princess Margaret Hospital and University of Chicago phase II consortia.
|
|
Academic Article
|
Randomized phase II trials: a long-term investment with promising returns.
|
|
Academic Article
|
Multicenter phase II trial of the heat shock protein 90 inhibitor, retaspimycin hydrochloride (IPI-504), in patients with castration-resistant prostate cancer.
|
|
Academic Article
|
Does androgen-deprivation therapy accelerate the development of frailty in older men with prostate cancer?: a conceptual review.
|
|
Academic Article
|
Phase II study of axitinib in sorafenib-refractory metastatic renal cell carcinoma.
|
|
Academic Article
|
Pazopanib in renal cell carcinoma.
|
|
Academic Article
|
A trial postmortem: challenges in conducting a randomized, double-blind, phase 2 study in men with castration-resistant prostate cancer.
|
|
Academic Article
|
Phase II and pharmacodynamic studies of pyrazine diazohydroxide (NSC 361456) in patients with advanced renal and colorectal cancer.
|
|
Academic Article
|
Granulocyte-macrophage-colony stimulating factor in combination immunotherapy for patients with metastatic renal cell carcinoma: results of two phase II clinical trials.
|
|
Academic Article
|
Nilutamide: possible utility as a second-line hormonal agent.
|
|
Academic Article
|
Antiandrogen withdrawal alone or in combination with ketoconazole in androgen-independent prostate cancer patients: a phase III trial (CALGB 9583).
|
|
Academic Article
|
Quality of life impact of three different doses of suramin in patients with metastatic hormone-refractory prostate carcinoma: results of Intergroup O159/Cancer and Leukemia Group B 9480.
|
|
Academic Article
|
Activities and accomplishments of the cancer and leukemia group B genitourinary committee.
|
|
Academic Article
|
Other paradigms: randomized discontinuation trial design.
|
|
Academic Article
|
Vascular endothelial growth factor pathway-targeted therapy as initial systemic treatment of patients with renal cancer.
|
|
Academic Article
|
Baseline patient-reported kidney cancer-specific symptoms as an indicator for median survival in sorafenib-refractory metastatic renal cell carcinoma.
|
|
Academic Article
|
A randomized, phase II study of pazopanib in castrate-sensitive prostate cancer: a University of Chicago Phase II Consortium/Department of Defense Prostate Cancer Clinical Trials Consortium study.
|
|
Academic Article
|
Renal cancer therapeutics: now what?
|
|
Academic Article
|
Estimation of renal cell carcinoma treatment effects from disease progression modeling.
|
|
Academic Article
|
Axitinib in metastatic renal cell carcinoma: results of a pharmacokinetic and pharmacodynamic analysis.
|
|
Academic Article
|
Phase 2 trial of dovitinib in patients with progressive FGFR3-mutated or FGFR3 wild-type advanced urothelial carcinoma.
|
|
Academic Article
|
An open-label, single-arm, phase 2 trial of the Polo-like kinase inhibitor volasertib (BI 6727) in patients with locally advanced or metastatic urothelial cancer.
|
|
Academic Article
|
Significance of lymphovascular invasion in organ-confined, node-negative urothelial cancer of the bladder: data from the prospective p53-MVAC trial.
|
|
Academic Article
|
Double-blind, randomized, phase 2 trial of maintenance sunitinib versus placebo after response to chemotherapy in patients with advanced urothelial carcinoma.
|
|
Academic Article
|
Phase II study of the oral MEK inhibitor selumetinib in advanced acute myelogenous leukemia: a University of Chicago phase II consortium trial.
|
|
Academic Article
|
The combination of insulin-like growth factor receptor 1 (IGF1R) antibody cixutumumab and mitotane as a first-line therapy for patients with recurrent/metastatic adrenocortical carcinoma: a multi-institutional NCI-sponsored trial.
|
|
Academic Article
|
FDG-PET as a predictive biomarker for therapy with everolimus in metastatic renal cell cancer.
|
|
Academic Article
|
Saracatinib as a metastasis inhibitor in metastatic castration-resistant prostate cancer: A University of Chicago Phase 2 Consortium and DOD/PCF Prostate Cancer Clinical Trials Consortium Study.
|
|
Academic Article
|
First-in-human multicenter phase I study of BMS-936561 (MDX-1203), an antibody-drug conjugate targeting CD70.
|
|
Academic Article
|
Trial Design and Objectives for Castration-Resistant Prostate Cancer: Updated Recommendations From the Prostate Cancer Clinical Trials Working Group 3.
|
|
Academic Article
|
Adjuvant sunitinib or sorafenib for high-risk, non-metastatic renal-cell carcinoma (ECOG-ACRIN E2805): a double-blind, placebo-controlled, randomised, phase 3 trial.
|
|
Academic Article
|
Immunomodulatory Activity of Nivolumab in Metastatic Renal Cell Carcinoma.
|
|
Academic Article
|
Clinical Evaluation of Cisplatin Sensitivity of Germline Polymorphisms in Neoadjuvant Chemotherapy for Urothelial Cancer.
|
|
Academic Article
|
Analyzing the clinical actionability of germline pharmacogenomic findings in oncology.
|
|
Academic Article
|
Phase II randomized, double-blind, placebo-controlled study of tivantinib in men with asymptomatic or minimally symptomatic metastatic castration-resistant prostate cancer (mCRPC).
|
|
Academic Article
|
Cabozantinib in advanced non-clear-cell renal cell carcinoma: a multicentre, retrospective, cohort study.
|
|
Academic Article
|
Complete response of renal cell carcinoma vena cava tumor thrombus to neoadjuvant immunotherapy.
|
|
Academic Article
|
The future of perioperative therapy in advanced renal cell carcinoma: how can we PROSPER?
|
|
Academic Article
|
Atezolizumab plus bevacizumab versus sunitinib in patients with previously untreated metastatic renal cell carcinoma (IMmotion151): a multicentre, open-label, phase 3, randomised controlled trial.
|
|
Academic Article
|
A randomized phase 2 study of temsirolimus and cetuximab versus temsirolimus alone in recurrent/metastatic, cetuximab-resistant head and neck cancer: The MAESTRO study.
|
|
Academic Article
|
Prevalence of potential interactions of medications, including herbs and supplements, before, during, and after chemotherapy in patients with breast and prostate cancer.
|
|
Academic Article
|
Angiokines Associated with Targeted Therapy Outcomes in Patients with Non-Clear Cell Renal Cell Carcinoma.
|
|
Concept
|
Antineoplastic Agents, Immunological
|
|
Academic Article
|
Optimizing the doses of cancer drugs after usual dose finding.
|
|
Academic Article
|
Belzutifan versus Everolimus for Advanced Renal-Cell Carcinoma.
|
|
Academic Article
|
Drug dosing in cancer patients with decreased kidney function: A practical approach.
|